Cargando…

Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report

Patient: Female, 52-year-old Final Diagnosis: Epithelial ovarian cancer with central nervous system involvement Symptoms: Abdominal pain • convulsions • dyspnea • weigh loss Medication: — Clinical Procedure: — Specialty: Oncology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Despi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vásquez, Flavia Morales, Basave, Horacio Noé López, Herrera, María del Carmen Méndez, González, Ricardo Raziel Peña
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704057/ https://www.ncbi.nlm.nih.gov/pubmed/33226974 http://dx.doi.org/10.12659/AJCR.925990

Ejemplares similares

High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma
por: Morales-Vásquez, Flavia, et al.
Publicado: (2016)

Sexual steroid hormone receptors profiles of ovarian carcinoma in Mexican women
por: Gómora, María J, et al.
Publicado: (2018)

Simultaneous expression of steroid sulfatase and androgen receptor reduced overall survival of patients with epithelial ovarian tumors
por: Calvillo-Robledo, Argelia, et al.
Publicado: (2021)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors
por: Morales-Vásquez, Flavia, et al.
Publicado: (2020)

Major complications following exenteration in cases of pelvic malignancy: an 18-year experience
por: Lopez-Basave, Horacio, et al.
Publicado: (2007)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
por: Baglo, Yan, et al.
Publicado: (2021)

GIST in a reference cancer center in México
por: López-Basave, Horacio Noe, et al.
Publicado: (2007)

Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution
por: López-Basave, Horacio N, et al.
Publicado: (2012)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
por: Gallardo-Rincón, Dolores, et al.
Publicado: (2022)

Estrogen and androgen receptor expression in surface epithelium and inclusion cyst in the ovary of premenopausal and postmenopausal women
por: Mendez, Carmen, et al.
Publicado: (2013)

Comment on evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
por: Madariaga, Ainhoa, et al.
Publicado: (2021)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Primary Gastric Hemangioblastoma: Report of a Case
por: Basave, Horacio N. López, et al.
Publicado: (2015)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
por: Shaw, Heather M, et al.
Publicado: (2013)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System
por: Tamura, Ryota
Publicado: (2023)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Intensive Care Unit Admission after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Is It Necessary?
por: López-Basave, Horacio N., et al.
Publicado: (2014)

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
por: Nepal, Gaurav, et al.
Publicado: (2022)

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
por: Choy, Edwin, et al.
Publicado: (2014)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
por: Cheng, Yuan, et al.
Publicado: (2018)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis?
por: López-Basave, Horacio Noé, et al.
Publicado: (2013)

Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol
por: Takagi, Masatoshi, et al.
Publicado: (2019)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jn3o2chj60oapdabg2jdgeunde